Search clinical trials for: Datopotamab deruxtecan Durvalumab
Total 841 results
-
Daiichi SankyoAstraZenecaActive, not recruitingNon-small Cell Lung CancerUnited States, Spain, Korea, Republic of, Taiwan, Germany, Italy, Japan, France, Hungary, Netherlands
-
Medical University of ViennaDaiichi Sankyo, Inc.Recruiting
-
Daiichi SankyoAstraZenecaAvailableAdvanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung CancerUnited States
-
AstraZenecaDaiichi SankyoActive, not recruitingCarcinoma, Non-Small-Cell Lung | Triple Negative Breast CancerChina
-
AstraZenecaDaiichi SankyoRecruitingAdvanced or Metastatic NSCLCUnited States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
-
Sarah Sammons, MDDaiichi SankyoRecruitingBreast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast CancerUnited States
-
AstraZenecaDaiichi SankyoNot yet recruitingNon-small Cell Lung CancerChina, Taiwan, Korea, Republic of, Australia
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.RecruitingTriple Negative Breast Cancer | Non-small Cell Lung Cancer | Hormone Receptor Positive Breast CancerUnited States, Japan
-
AstraZenecaRecruitingTriple Negative Breast NeoplasmsUnited States, Korea, Republic of, Canada, Taiwan, United Kingdom, Poland
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZenecaRecruitingMetastatic Non Small Cell Lung CancerUnited States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
-
AstraZenecaRecruitingAdvanced Solid MalignanciesUnited States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom
-
AstraZenecaSWOG Clinical Trials Partnerships; Daiichi SankyoRecruitingBreast CancerUnited States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
-
Daiichi SankyoAstraZenecaActive, not recruitingNon-small Cell Lung CancerUnited States, Germany, Spain, Japan, Canada, France, Korea, Republic of, Italy, United Kingdom, China, Taiwan, Hungary, Singapore, Switzerland, Netherlands, Brazil, Mexico, Russian Federation, Puerto Rico, Poland, Hong Kong, Romania and more
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZenecaActive, not recruitingAdvanced or Metastatic NSCLCUnited States, Spain, Taiwan, Japan, Italy
-
AstraZenecaDaiichi SankyoNot yet recruitingNon-Small Cell Lung CancerItaly, Spain, Poland, Canada, Korea, Republic of, Hungary, Turkey, Taiwan, United Kingdom, Japan, Austria, Australia, Germany, Brazil
-
Daiichi Sankyo, Inc.AstraZenecaRecruiting
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, France, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Turkey, Brazil, Japan, Taiwan, Thailand, Canada, Singapore, Mexico, Argentina, Germany, India, Philippines, Poland, South Africa
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast AdenocarcinomaUnited States
-
AstraZenecaRecruitingNSCLCChina, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast CancerBelgium, Canada, France, Italy, Spain, United Kingdom, Hungary, Poland, United States, Korea, Republic of, Brazil, India, Japan, Russian Federation, China, Taiwan, Netherlands, Germany, South Africa, Argentina
-
Daiichi SankyoAstraZenecaRecruitingBreast Cancer | Advanced Solid TumorUnited States, Spain, Canada, France
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingRecurrent or Metastatic Solid TumorsUnited States
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Advanced Solid TumorJapan
-
The Netherlands Cancer InstituteDaiichi Sankyo, Inc.Not yet recruitingEGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
-
SCRI Development Innovations, LLCDaiichi Sankyo, Inc.RecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerUnited States
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZenecaRecruitingMetastatic Non Small Cell Lung CancerBelgium, Australia, United States, Korea, Republic of, Spain, China, France, Thailand, Brazil, Japan, Germany, Romania, Hungary, Italy, Taiwan, Austria, Canada, Hong Kong, Argentina, Netherlands, Chile, Greece, Poland
-
Daiichi Sankyo, Inc.TerminatedMetastatic Colorectal CancerUnited States, Spain, Belgium, Japan, France, United Kingdom, Italy, Poland
-
AstraZenecaDaiichi SankyoCompletedBreast CancerDenmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
-
Daiichi Sankyo Co., Ltd.Daiichi Sankyo, Inc.CompletedMetastatic Breast CancerUnited States, Japan
-
AstraZenecaDaiichi SankyoRecruitingLocally Advanced or Metastatic Non-Small Cell Lung CancerKorea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
-
Gruppo Oncologico del Nord-OvestRecruitingColorectal Cancer | Resectable Colorectal CarcinomaItaly
-
Samsung Medical CenterNot yet recruitingSolid Tumor, AdultKorea, Republic of
-
AstraZenecaActive, not recruitingNon-Small Cell Lung CancerDenmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
-
Fudan UniversityNot yet recruitingTriple-Negative Breast CancerChina
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
AstraZenecaActive, not recruitingNon-Small Cell Lung CancerFrance, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
-
Daiichi SankyoActive, not recruitingEGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung CancerKorea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingExtensive-stage Small-cell Lung CancerUnited States, Korea, Republic of, Spain, Taiwan, France, Japan, Germany, China, Austria
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingGastric or Gastroesophageal Junction (GEJ) AdenocarcinomaChina